Artesunate

Artesunate
Clinical data
Pronunciation	ahr-tez′ŭ-nāt
Trade names	many
Other names	SM-804
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Artesunate;
Routes of; administration	By mouth, intravenous, intramuscular
Drug class	Artemisinin
ATC code	P01BE03 (WHO) P01BF02 (WHO) P01BF03 (WHO) P01BF04 (WHO) P01BF06 (WHO);
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	88495-63-0 ; as salt: 82864-68-4;
PubChem CID	6917864; as salt: 44410736;
DrugBank	DB09274 ; as salt: DBSALT001279;
ChemSpider	5293084 ; as salt: 23269779;
UNII	60W3249T9M; as salt: CN5E49Z611;
KEGG	D02482;
ChEBI	CHEBI:63918;
ChEMBL	ChEMBL361497 ; as salt: ChEMBL207675;
NIAID ChemDB	112081;
PDB ligand	D95 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID3042681 ;
ECHA InfoCard	100.106.898
Chemical and physical data
Formula	C19H28O8
Molar mass	384.425 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@@]12CC[C@@]3(C)OO[C@@]11[C@@]([H])(CC[C@H]2C)[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@]1([H])O3;
	InChI InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1 ; Key:FIHJKUPKCHIPAT-AHIGJZGOSA-N ;
	(what is this?) (verify)

Artesunate (AS) is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum.

The most common side effects include kidney failure requiring dialysis, hemoglobinuria (the presence of hemoglobin in urine) and jaundice.

Artesunate is generally well tolerated. Side effects may include a slow heartbeat, allergic reaction, dizziness, and low white blood cell levels. During pregnancy it appears to be a safer option, even though animal studies have found harm to the baby. Use is likely fine during breastfeeding. It is in the artemisinin class of medication.

Artesunate was developed by Liu Xu in 1977. It is on the World Health Organization's List of Essential Medicines. It was approved for medical use in the United States in May 2020. It is in the class of medications known as artemisinins, which are derivatives from "qinghao," or sweet wormwood plant (Artemisia annua).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.